03.07.2024 08:17:22
|
Syncona Invests In Beacon's Series B Financing - Quick Facts
(RTTNews) - Syncona (SYNC.L) said it has committed $42.5 million to a $170 million Series B financing of its portfolio company Beacon Therapeutics. Including this, Syncona's holding value of Beacon will be $131.9 million, and on drawdown of the full Series B financing, Syncona's ownership stake in the business will be 41.4 percent.
Beacon Therapeutics is an ophthalmic gene therapy company. Lead development candidate AGTC-501, is a gene therapy program currently being investigated for the treatment of XLRP.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!